Explaining how antidepressants work without the chemical-imbalance myth (CASC)

Station instructions (candidate)

You have 7 minutes. Explain how sertraline is thought to help depression in accurate plain language, set expectations for time course and common side-effects, and address the tramadol and alcohol risks. Do not use a simplistic “low serotonin top-up” model as settled science. Anchor hope in treatment evidence while remaining scientifically honest.[1][3][5]

Marking domains

Mark agenda setting and empathy; accurate mechanism without myth; delayed adaptation explanation; side-effect warning without catastrophising; active drug-interaction safety (tramadol/serotonergic risk); alcohol caution; shared decision and follow-up plan. These domains test whether mechanism knowledge improves consent rather than becoming jargon.[2][4][5]

Model communication map

1. Open: thank them; check their understanding of depression and goals (sleep, concentration, work return).[5]
2. Honest mechanism: sertraline blocks the serotonin reuptake pump (SERT) so signalling changes at synapses; the brain then adapts over weeks — it is not proven that you simply “lack serotonin like insulin deficiency.”[1][2][3]
3. Why it still helps: many people improve on antidepressants; we choose and monitor based on evidence and your priorities, not a blood serotonin test.[5]
4. Time course: early side-effects possible; meaningful mood benefit often takes weeks; early review for activation, sleep, suicidal thoughts.[2][5]
5. Tramadol risk: combining serotonergic medicines can rarely cause serotonin toxicity (agitation, tremor, clonus, fever) — we need a pain-plan review with their GP/prescriber.[4]
6. Alcohol: both alcohol and some medicines sedate via related brain inhibition pathways; alcohol also worsens mood/sleep — negotiate harm reduction.[1]
7. Close: starting dose plan, written info, crisis contacts, review timing, questions.[5]

Common fails

• Endorsing “you have low serotonin; this replaces it” as fact.[3]
• Ignoring tramadol serotonergic interaction risk.[4]
• Promising same-week cure or denying any evidence of benefit.[5]
• Flooding with receptor subtype names without checking understanding.[1]